Thrombotic events
Disease1 paper1 finding
- Humans1
Associations
1GLP-1 receptor agonists
downin humans1HR 0.53
1 study
GLP-1 receptor agonists
downin humans1HR 0.53
GLP-1 receptor agonists lower the risk of thrombotic events in humans (HR, 0.53; 95% CI, 0.32-0.89).
Humansversus DPP-4i in men with prostate cancer undergoing ADT and T2Dmalesn = 659
Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy · Frontiers in urology · 7 Aug 2026
Latest
8Blood AdvancesHumans
Metformin linked to fewer clots in blood cancer and diabetes
Metformin users had lower blood clot risk than non-users, with a hazard ratio of 0.78, a measure comparing risk over time.Metformin users had lower blood clot risk than non-users, with a hazard ratio of 0.78, a measure comparing risk over time.
International Journal of CancerHuman trial
Is Less More? An Update on Aspirin for Cancer Prevention in Lynch Syndrome From the Cancer Prevention Programme-CaPP
Seminars in Thrombosis and HemostasisReview
Advances from Traditional Clinical Decision Support Tools to Machine Learning Applications in Primary Prevention of Thromboembolic Disorders
European Journal of Internal MedicineHumans
Long-term vascular outcomes and biological predictors of thrombosis in systemic lupus erythematosus: a 10-year prospective cohort study
AHA Scientific Sessions 2025 AbstractHumans